Pars Isotope Co
- Home
- Companies
- Pars Isotope Co
- Products
5 products found
Pars Isotope Co products
Generators
Pars Isotope - Tc-99m Generator for Diagnostic Use
The PARSTEC II generator, manufactured by Parsisotope, is a crucial product in the realm of nuclear medicine. Designed for the extraction of technetium-99m (Tc-99m) in the form of a sodium pertechnetate solution, it serves as an essential tool for labeling SPECT diagnostic radiopharmaceutical kits. It facilitates the diagnosis of various cancers and diseases. Tc-99m is favored in medical diagnostics due to its half-life of 6.01 hours, which limits unnecessary radiation exposure while emitting gamma rays at 140 keV, sufficient for penetrating tissue for detailed diagnostic results. The generator has a productive lifespan determined by the three half-lives of its parent isotope, molybdenum-99, approximately a week, thereby establishing it as a staple in consistent weekly production. Parsisotope ensures this generator complies with GMP standards and remains competitive among global Tc-99m generators.Radiopharmaceutical
Pars Isotope - Radiopharmaceutical for PET Imaging
FDG, or Fluoro Deoxy Glucose, is a pivotal radiopharmaceutical utilized in positron emission tomography (PET) imaging. This compound capitalizes on the principle of metabolic trapping to use a radioactive tracer to directly evaluate the body's metabolic functions. FDG's utilization in whole-body PET imaging substantially enhances the capabilities for cancer diagnosis and staging, supports the selection of appropriate treatment options, and facilitates the evaluation of therapeutic responses. Cancer, although typically originating within a single organ, is a systemic disease, with metastatic spread to additional organs posing significant challenges. FDG's application in rapid diagnosis and the quantitative assessment of metastases makes it a critical tool in medical imaging, offering insights that drive effective treatment strategies.
Pars Isotope - Theranostic Radiopharmaceutical for Prostate Cancer Treatment
Lu-177-PSMA is a theranostic radiopharmaceutical designed for the treatment of metastatic prostate cancer. Employing the Peptide Receptor Radionuclide Therapy (PRRT) technique, it selectively targets and binds to prostate tumor cells, facilitating the destruction of malignant cells. This unique action stems from its characteristic as a gamma emitter, allowing not only for therapeutic intervention but also for imaging and monitoring of treatment progress. Ideal for precision oncology, Lu-177-PSMA combines targeted therapeutic effectiveness with diagnostic capabilities, playing a crucial role in managing advanced prostate cancer cases by enabling both treatment and detailed imaging follow-up.Radiopharmaceutical Kits - Theranostic
Pars Isotope - Theranostic Radiopharmaceutical Kit for Neuroendocrine Tumor Treatment
The PARS-LUTOTATE theranostic radiopharmaceutical kit is an innovative solution formulated as a single vial for the effective treatment of neuroendocrine tumors. It utilizes the Lu-177 radioisotope, enabling the radiopharmaceutical to selectively target neuroendocrine tumor cells, facilitating their complete destruction. This procedure not only assists in treatment but also enhances diagnostic imaging capabilities for observing and tracking treatment progression. Neuroendocrine tumors, though relatively rare, originate from cells exhibiting characteristics akin to endocrine glands and nervous systems, potentially occurring throughout the body. Predominantly, these tumors are located in the lungs, appendix, small intestine, rectum, and pancreas. The application of this kit signifies a significant advancement in the accurate detection and management of these specific cancer types.